Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions

Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms

(2014) Vaheh Oganesyan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antibodies to watch in 2014

(2014) Janice M Reichert   mAbs

Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody

(2014) Céline Monnet et al.   mAbs

Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy

(2014) A. Hiatt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Contribution of Human FcγRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies

(2014) Caitlin Gillis et al.   Frontiers in Immunology

A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

(2013) Gabriel J. Robbie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics

(2013) Timo Rath et al.   CRITICAL REVIEWS IN BIOTECHNOLOGY

FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activity

(2013) Rintaro Moroi et al.   IMMUNOGENETICS

Antibodies to watch in 2014

(2013) Janice M Reichert   mAbs

Immune suppression in cynomolgus monkeys by XPro9523

(2013) Matthew J. Bernett et al.   mAbs

Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities

(2013) Susan H. Tam et al.   mAbs

Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies

(2013) Gabriele Proetzel et al.   METHODS

Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo

(2013) Tomoyuki Igawa et al.   PLoS One

Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery

(2013) E. M. Pridgen et al.   Science Translational Medicine

Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab

(2012) A Ruyssen-Witrand et al.   ANNALS OF THE RHEUMATIC DISEASES

Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia

(2012) Nichola Cooper et al.   BRITISH JOURNAL OF HAEMATOLOGY

Development of an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody with Potent Antitumor Activity

(2012) D. Loo et al.   CLINICAL CANCER RESEARCH

The interactions of therapeutic antibodies with Fc receptors

(2012) Marcello Albanesi et al.   IMMUNOLOGY LETTERS

Marketing approval of mogamulizumab

(2012) Alain Beck et al.   mAbs

Autonomous phagosomal degradation and antigen presentation in dendritic cells

(2012) E. Hoffmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Whole-Molecule Antibody Engineering: Generation of a High-Affinity Anti-IL-6 Antibody with Extended Pharmacokinetics

(2011) Donna K. Finch et al.   JOURNAL OF MOLECULAR BIOLOGY

Neonatal Fc receptor and IgG-based therapeutics

(2011) Timothy T. Kuo et al.   mAbs

Efficient mucosal vaccination mediated by the neonatal Fc receptor

(2011) Lilin Ye et al.   NATURE BIOTECHNOLOGY

Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells

(2011) K. Baker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant

(2011) L. Zeitlin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Therapeutic Anti-VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life

(2010) Y. A. Yeung et al.   CANCER RESEARCH

Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-  Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys

(2010) R. Deng et al.   DRUG METABOLISM AND DISPOSITION

Neonatal Fc Receptor: From Immunity to Therapeutics

(2010) Timothy T. Kuo et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Identification of IgG1 variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: Comparison of soluble receptor-based and cell-based binding assays

(2010) Yanmei Lu et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies

(2010) M Le Garff-Tavernier et al.   LEUKEMIA

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

(2010) Gregory L. Moore et al.   mAbs

Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization

(2010) Tomoyuki Igawa et al.   NATURE BIOTECHNOLOGY

Enhanced antibody half-life improves in vivo activity

(2010) Jonathan Zalevsky et al.   NATURE BIOTECHNOLOGY

Optimization of Fc-mediated effector functions of monoclonal antibodies

(2009) William R Strohl   CURRENT OPINION IN BIOTECHNOLOGY

Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding

(2009) Jan Terje Andersen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

(2009) Frédéric Bibeau et al.   JOURNAL OF CLINICAL ONCOLOGY

Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates

(2009) Y. A. Yeung et al.   JOURNAL OF IMMUNOLOGY

Structural characterization of a human Fc fragment engineered for extended serum half-life

(2009) Vaheh Oganesyan et al.   MOLECULAR IMMUNOLOGY

A human anti-D monoclonal antibody selected for enhanced FcγRIII engagement clears RhD+autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies

(2008) Roland Beliard et al.   BRITISH JOURNAL OF HAEMATOLOGY

Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16

(2008) Christophe de Romeuf et al.   BRITISH JOURNAL OF HAEMATOLOGY

Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia

(2008) H. M. Horton et al.   CANCER RESEARCH

When binding is enough: nonactivating antibody formats

(2008) Aran F Labrijn et al.   CURRENT OPINION IN IMMUNOLOGY

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells

(2008) J. O. Richards et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies

(2008) Seung Y. Chu et al.   MOLECULAR IMMUNOLOGY

Dependence of antibody-mediated presentation of antigen on FcRn

(2008) S.-W. Qiao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA